Full Press Release Details
Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA ART Device
entered a non-binding Letter of Intent
Israel, February 08, 2024 - Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company"
or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has
announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution
in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical
deployment strategy.
solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA ART100 device ("Device)
within Shamir Medical Center's clinical environment. This includes evaluating the device's fit with the hospital's clinical needs, efficiency
in workflow, and overall impact on healthcare delivery. The hospital will procure all required disposables for operating the Devices as
part of the LOI. Inspira will gain access to device operation data and user experience in a real-life clinical setting. The evaluation
will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care
medicine in Israel. The progression of this LOI hinges on the AMAR (medical devices and accessories) approval by the Israeli Ministry
of Health for the Device, and the subsequent formalization of a detailed definitive evaluation agreement between the parties.
President of Inspira Technologies, stated: "With the anticipated U.S. Food and Drug Administration (FDA) approval on the horizon,
I am confident that this prospective collaboration with Shamir Medical Center will enhance the efficacy of life-support care and establish
a pathway for its adoption in both local and international markets."
About Shamir Medical Center (Assaf Harofeh)
Shamir Medical Center (Assaf Harofeh), Israel's fourth-largest
government hospital, is a beacon of advanced medical care, serving over 1 million residents in the central region. Known for its state-of-the-art
facilities and commitment to medical innovation, the hospital is currently transforming to meet the growing population's needs.
Renowned for its excellence in critical care, the Intensive Care Unit (ICU) at Shamir Medical Center is a model of innovation, particularly
in Extracorporeal Membrane Oxygenation (ECMO) expertise. With a focus on patient-centered interventions, the ICU leads in awake ECMO treatment,
demonstrating a dedication to advancing critical care during the COVID-19 pandemic. Overall, Shamir Medical Center remains at the forefront
of medical excellence, contributing significantly to the global medical community through publications, ongoing research projects, and
a commitment to pushing the boundaries of critical care.
About Inspira Technologies OXY BHN Ltd.
Technologies is leading the way in transforming life-support care. Its innovative solutions are paving the way for direct blood oxygenation,
bypassing the lungs, and potentially reducing the need for traditional mechanical ventilation. Beyond this, the Company is committed to
advancing blood circulation technology and incorporating AI-driven monitoring systems. These advancements are part of its strategy to
offer more patient-focused, data-informed care. The integration of these technologies signifies the potential to enhance patient outcomes
and streamline hospital operations, marking a new era in respiratory care.
For more information, please
visit our corporate website:
Forward-Looking Statement Disclaimer
This press release contains express or implied
forward-looking statements under US Federal securities laws. These forward-looking statements and their implications are based only on
the current expectations of the management of the Company. They are subject to several factors and uncertainties that could cause results
to differ materially from those described in the forward-looking statements. For example, the Company uses forward-looking statements
when it discusses the potential for executing the definitive agreement, that it plans to extend collaborations with further leading Israeli
medical centers as part of a wider clinical deployment strategy, the proposed evaluation of the Device by Shamir Medical Center, the expected
timing of FDA approval of the Device, that the progress of the LOI hinges on the AMAR approval by the Israeli Ministry of Health for the
Device, and the subsequent formalization of a detailed definitive evaluation agreement between the parties, the belief that the prospective
collaboration with Shamir Medical Center will enhance the efficacy of life-support care and establish a pathway for its adoption in both
local and international markets and its vision to supersede traditional mechanical ventilators. Except as otherwise required by
law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal
year ended December 31, 2022, filed with the SEC, which is available on the SEC's website, www.sec.gov.
Public Relations Manager
Inspira Technologies
Copyright 2018-2023 Inspira Technologies